Feasibility of Bi-Phase Retinal Essence Formulation

Asked by: athip_1995 On: September 19, 2019 Product Type: Cosmetics

Question

I would like to request custom manufacturing for a Retinal Essence in a semi-bi-phase form, for nighttime use. Can the following ingredients be included in the formulation?

Active Ingredients:

  • 5% ActiveRelease Retinal™
  • 0.2% Phytosphingosine SA

Oils:

  • 3% Argan Oil
  • 3% Sea Buckthorn Oil
  • 3% Rose Hip Oil
  • 2% Squalane
  • 2% Jojoba Oil
  • 1% Oat Oil
  • 1% Safflower Oil
  • 1% Borage Oil
  • 1% Echium Oil
  • 1% Pomegranate Oil
  • 1% Raspberry Oil
  • 1% Shea Butter Melt
  • 0.5% Natural Bisabolol
  • 0.5% dl-alpha tocopherol

Water:

  • 60.4% Rosa Damascena Flower Water

Emulsifier/Emollient:

  • 4% Light Lotion Maker
  • 0.2% Satin Cream Maker™
  • 3% Dimethyl Isosorbide
  • 5% LipidSoft™ Dry II

Preservatives:

  • 1% Mild Preserved Eco™
  • 0.2% Disodium EDTA

Answer

Based on the formulation you've proposed for a semi-bi-phase Retinal Essence, I can provide an assessment based on the properties of the ingredients you've listed.

Your formulation includes a rich blend of active ingredients and natural oils, aiming for a semi-bi-phase texture. However, there are significant challenges in combining these specific ingredients in a stable semi-bi-phase system, particularly concerning the active ingredients and the chosen emulsifiers.

Here are the key points to consider:

  • Conflicting Requirements for Active Ingredients:
    • ActiveRelease Retinal™: The description for ActiveRelease Retinal™ states it should be mixed in the oil phase and avoid heat. It's encapsulated for stability and sustained release. It also suggests using ActiveProtec™ OX and potentially Vitamin B3 (Niacinamide) for enhanced stability and reduced irritation, which are not included in your list.
    • Phytosphingosine SA: The description for Phytosphingosine SA requires heating the oil phase to 80-90°C for complete dissolution and needs high-speed blending. It also requires a specific co-solvent like Octyldodecanol at a high percentage (12-14% for 0.2% SA), which is not listed in your oil phase.

The requirement to heat the oil phase to a high temperature for Phytosphingosine SA directly conflicts with the need to avoid heat for ActiveRelease Retinal™. This makes it very difficult, if not impossible, to incorporate both active ingredients effectively and maintain their stability and efficacy within the same formulation using standard manufacturing processes.

  • Emulsifier Choice vs. Bi-Phase Nature:

    • You've included Light Lotion Maker and Satin Cream Maker™. These are designed to create stable emulsions (lotions or creams) by binding oil and water phases together.
    • A true semi-bi-phase product relies on minimal or no emulsification, allowing the oil and water phases to separate and requiring shaking before use for temporary dispersion.
    • Using these emulsifiers at the proposed percentages (4% and 0.2%) with a 22% oil phase is likely to result in a stable emulsion (lotion or cream), not a semi-bi-phase product.
  • Formulation Complexity:

    • Combining a large number of diverse oils (12 different types) in a semi-bi-phase system, even with emulsifiers, adds complexity and potential stability challenges (like phase separation or changes in texture over time).
    • Dimethyl Isosorbide is a penetration enhancer that can help deliver ingredients, but its interaction with the other components and its role in a semi-bi-phase system with these specific emulsifiers would need careful validation.

Conclusion:

Based on the technical requirements of the ingredients, particularly the conflicting temperature sensitivities of ActiveRelease Retinal™ and Phytosphingosine SA, and the inclusion of emulsifiers that promote stable emulsions rather than a bi-phase separation, this specific formulation as written is likely not feasible to manufacture as a stable semi-bi-phase product.

Achieving a stable and effective product with these desired active ingredients and a bi-phase texture would require significant formulation expertise, potentially involving alternative forms of the active ingredients, different emulsification strategies suitable for bi-phase systems, or a complete reformulation approach.